ASCO 2026: Cellectar's Waldenström Macroglobulinemia Data

Key Takeaways

• Cellectar Biosciences will present subset data from the CLOVER WaM trial of iopofosine I 131 at ASCO 2026.
• The presentation will focus on efficacy data in relapsed/refractory Waldenström macroglobulinemia patients who have previously been treated with a BTK inhibitor.
• ASCO 2026 is scheduled to take place from May 29 to June 2 in Chicago, Illinois.

Cellectar Biosciences (NASDAQ: CLRB) is set to present data from its CLOVER WaM trial at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2, 2026, in Chicago. The presentation will highlight efficacy subset data for iopofosine I 131 in patients with relapsed or refractory Waldenström macroglobulinemia.

The ASCO Annual Meeting is a major event in the oncology field, bringing together researchers and clinicians to discuss the latest advancements in cancer treatment and care. The conference is known for featuring late-breaking abstracts and presentations of significant clinical trial data, making it an important venue for companies like Cellectar to share their findings.

CLOVER WaM Trial Details

The CLOVER WaM trial is evaluating the use of iopofosine I 131 in Waldenström macroglobulinemia patients who have relapsed or are refractory to prior treatment, specifically after Bruton's tyrosine kinase (BTK) inhibitor therapy. The upcoming presentation will be a poster presentation focusing on a subset of efficacy data from this trial.

ASCO 2026 Overview

The ASCO Annual Meeting is a premier oncology conference where researchers present late-breaking abstracts and findings from clinical trials. This year's meeting will be held in Chicago from May 29 to June 2, 2026.

Market & Investor Implications

The presentation of CLOVER WaM data at ASCO 2026 could have implications for Cellectar Biosciences' stock and market position, depending on the strength and reception of the presented data.

What to Watch Next

Investors and clinicians will be keenly watching the detailed results presented at the ASCO meeting to understand the potential of iopofosine I 131 in treating Waldenström macroglobulinemia. Further updates from Cellectar regarding the CLOVER WaM trial are also anticipated.

Frequently Asked Questions

• What is Waldenström macroglobulinemia?

  Waldenström macroglobulinemia is a rare type of non-Hodgkin lymphoma characterized by the overproduction of abnormal white blood cells.

• What is iopofosine I 131?

  Iopofosine I 131 is a targeted radiotherapeutic being developed by Cellectar Biosciences.

• What is the CLOVER WaM trial?

  The CLOVER WaM trial is a clinical trial investigating the use of iopofosine I 131 in patients with relapsed or refractory Waldenström macroglobulinemia post BTK inhibitor therapy.

• When and where is ASCO 2026 taking place?

  ASCO 2026 will be held from May 29 to June 2 in Chicago, Illinois.

• Why is the ASCO presentation important?

  The ASCO presentation is an opportunity for Cellectar to share important efficacy data from the CLOVER WaM trial with the oncology community.

References

• Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026. [https://www.cellectar.com/investors/news-events/press-releases/detail/388/cellectar-biosciences-announces-subset-of-clover-wam-clinical-trial-data-accepted-for-presentation-at-the-american-society-of-clinical-oncology-conference-2026]